Hem › Atopisk dermatit (eksem) › Arkansas
Kliniska studier för Atopisk dermatit (eksem) i Arkansas
8 studier för Atopisk dermatit (eksem) söker deltagare vid platser i Arkansas.
Städer i Arkansas
Officiell studietext (engelska)
Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
- Novartis Investigative Site, Fort Smith
RekryterarFas 2
Ålder 18 till 100 · Alla kön · Uppdaterad 28 sep. 2026 · NCT06947993Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
- Enveda Investigative Site, Hot Springs
RekryterarFas 2
Ålder 18 till 75 · Alla kön · Uppdaterad 25 sep. 2026 · NCT07298395A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
- Arkansas Research Trials, North Little Rock
RekryterarFas 3
Ålder 2 till 11 · Alla kön · Uppdaterad 25 sep. 2026 · NCT06807281A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
- Dermatology Trial Associates, Inc, Bryant
RekryterarFas 2
Ålder 18 till 65 · Alla kön · Uppdaterad 28 aug. 2026 · NCT07599813A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
- Applied Research Center and Wellness Clinic /ID# 268547, Little Rock
RekryterarFas 3
Ålder 2 till 11 · Alla kön · Uppdaterad 6 aug. 2026 · NCT06461897A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
- Leo Pharma Investigational site, North Little Rock
RekryterarFas 3
6 Months – 11 Years · Alla kön · Uppdaterad 7 juli 2026 · NCT06311682A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
- Clinical Trials Institute - Northwest Arkansas /ID# 267290, Fayetteville
RekryterarFas 3
Ålder 18 till 63 · Alla kön · Uppdaterad 6 juli 2026 · NCT06389136A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Single and Multiple Dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis
- Arkansas Research Trials, North Little Rock
RekryterarFas 1
Ålder 18 och äldre · Alla kön · Uppdaterad 19 sep. 2025 · NCT06055361Från ClinicalTrials.gov, data hämtad 5 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.